Eurogin is part of the Informa Markets Division of Informa PLC


EUROGIN 2023 abstract submission deadline extended! New submission deadline: October 17


List of Sessions

HPV Vaccines

Scientific approaches towards improving the cervical cancer elimination strategies

M. Lehtinen (Finland) - E. Franco (Canada) - J. Dillner (Sweden)

Prevention of cervical cancer among people living with HIV

A. Giuliano (USA)

Women living with HIV are at elevated risk of acquiring oncogenic HPV infections, having those infections persist, and progress to cervical pre-cancer and cancer. Unfortunately, the performance of tests utilized among women without HIV to screen for cervical cancer and to treat pre-cancer lesions perform sub-optimally among women living with HIV. Current research is focused on tailoring these interventions for women living with HIV in a variety of different geographic regions. Also needed are interventions to improve CIN treatment outcomes among women living with HIV.

Monitoring HPV vaccine impact in males

A. Giuliano (USA) - J. Palefsky (USA)

HPV Vaccination in adult women

M. Elfström (Sweden) - M. Kyrgiou (UK)

Impact of HPV vaccine on cancer

P. Sasieni (UK) - J. Lei (Sweden)

HPV vaccination has been approved to be highly effective. In this session, we will gather researchers from six countries who will present the latest updates regarding the impact of HPV vaccination against cancer. We will address the evidence on the already observed impact from trials, routine vaccination programmes as well as modelling results focusing on the potential scale of the impact in terms of the current strategies.

HPV prevention and screening in vulnerable (immunosuppressed and transgender) populations

A. D’Souza (USA) - A. B. Moscicki (USA) - M. Goodman (USA)

Evolution of HPV vaccination schedules – form evidence to public health impact

S. Franceschi (Italy) - M. Jit (UK)

HPV Screening

Triage of HPV-positive women: how to select options for a screening program?

N. Wentzensen (USA) - H. Berkhof (Netherlands)

Self-sampling in routine practice, operational and technical issues

R. Bhatia (UK)

New guidelines for validation of HPV tests for cervical cancer screening

M. Arbyn (Belgium) - M. Poljak (Slovenia)

Quality assurance and validation of primary, triage testing and collection methods

K. Cuschieri (UK) - H. Berkhof (Netherlands)

The implementation and evolution of cervical screening programmes based on molecular HPV testing continues apace. To ensure tests and processes are fit for purpose before implementation - and in perpetuity - validation and quality monitoring of the end-to-end process is essential. This session will benefit from perspectives from laboratory experts, cancer epidemiologists and screening teams. Country specific approaches to quality processes will be discussed as will the perspectives of laboratory network(s). The challenges of validation given increased use of self-sampling and the greater emergence of immunised populations in screening will also be covered.

New screening algorithms in European countries

P. Hillemanns (Germany) - M. Arbyn (Belgium)

Moving from one-size-fits all screening to risk-based screening

N. Wentzensen (USA)

New triage methods

F. Carozzi (Italy) - J. Cuzick (UK)

Advanced molecular methods now allow better characterization of HPV infections detected by screening and enable optimization of cervical screening algorithms to differentiate women carrying HPV infection at lower or higher risk of precancerosis and cervical cancer. In this session, we will discuss and explore issues related to their introduction into screening programs to enable increasingly accurate risk stratification.

Benefits and harms of HPV screening

T. Malagon (Canada) - C. Bouchard (Canada)

All screening programs entail harms as well as benefits. A core principle of modern screening programs and guidelines is that the overall benefit of the screening program should outweigh its potential harms. However, the estimation and the communication of the balance of harms and benefits can be in practice complex. In this session we shall review harms and benefits of cervical cancer screening in the context of populations highly HPV vaccinated, examine the balance of harms and benefits for future anal cancer screening, and finish with related issues arising when implementing HPV-based screening, including methods for estimating the balance of benefits and harms of screening algorithms, and developing communication tools on the benefits and harms of screening for shared decision making.

Extended HPV genotyping in screening

J. Bonde (Denmark) - E. Franco (Canada)

Concomitant screening and vaccination

M. Elfström (Sweden) - M. Almonte (France)

The role of obesity in cervical cancer screening and management

M. Clarke (USA)

Obesity is a worldwide public health challenge, increasing the risk for several cancers including cervical cancer. Prior research has shown that individuals with obesity have a higher risk of cervical cancer, but a lower risk of precancer compared to those with normal BMI, which is thought to be at least in part explained by missed detection of precancers.  The current session addresses the impact of obesity on the effectiveness of cervical cancer screening and management.

Primary self-sampling strategies, what is the evidence

H. Berkhof (Netherlands)

Virology, Molecular Biology and Biomarkers

Tumour HPV status and implications for survival outcomes in cervical and non-cervical disease

K. Cuschieri (UK) - S. Arroyo Mühr (Sweden)

While it is well established that HPV status is strongly associated with clinical outcomes in oropharyngeal cancer, increasing evidence suggests that this phenomenon is consistent in other tumour types; this is reflected in the recent WHO update on gynae cancer classification that advises cervical tumours should be referred to as “HPV independent” or “HPV associated”. In this session, the basic molecular characteristics of HPV associated, and HPV independent neoplasms will be discussed in addition to optimal and evolving methods to determine HPV status as well as the implications and challenges of using HPV status for clinical management and treatment decisions.

HPV and host methylation as triage tools for cervical cancer screening in difference clinical contexts

C. Meijer (Netherlands) - M. Clarke (USA)

Prognostic Biomarkers for cervical HSIL progression

K. Louvanto (Finland) - B. Nedjai (UK)

This session will highlight strategies that could identify women with a progressive precancer cervical lesion to immediate referral to colposcopy compared to follow-up testing of women with intermediate risk. These strategies are needed to maximize the benefits of cervical cancer screening and follow-up testing while decreasing the potential harm as cost of unnecessary colposcopy referrals and treatments.


M. Arbyn (Belgium) - C. Cocuzza (Italy)

HPV latency

A. B. Moscicki (USA)

Next generation HPV based sequencing: what have we learned and what’s next?

K. Cuschieri (UK) - L. Mirabello (USA)

HPV detection using rapid next generation sequencing (NGS) technologies can provide insight into the molecular biology, epidemiology and clinical trajectory of HPV infection. In this session we reflect on recent developments and applications of NGS and how this has furthered our understanding of HPV in the context of anogenital and head and neck disease.


A.B. Moscicki (USA) - A. Lev Sagie (Israel)

Management and Follow up

HPV and pregnancy

K. Louvanto (Finland) - E. Siegler (Israel)

This session will focus on the most common concerns that women in childbearing age have on HPV infection and its consequences. The session will cover the current knowledge on the HPV role in reproductive life, during pregnancy and in children. We will also have a round table discussion on HSIL treatment options for pregnant women.

Management of CIN

E. Paraskevaidis (Greece)

Transmission - role of the male partner

M. Goodman (USA) - E. Franco (Canada)

Colposcopy in the HPV era

P. Hillemanns (Germany) - C. Bouchard (Canada)

VuIN update

J. Bornstein (Israel) - M. Bleeker (Netherlands)

VaIN Management

M. Preti (Italy) - M. Hampl (Germany)

Risk stratification in the follow up

F. Carozzi (Italy) - N. Wentzensen (USA)

Women treated for high grade lesions and women HPV positive/colposcopy negative represent an at-risk population compared to the routinely screened population. So, a combination of well-known risk factors associated to new Molecular markers could allow a better risk stratification of these women. Balancing the benefits of robust follow-up with the harms of over-scrutiny is particularly challenging. In this session we will review the international experience from real-life program and reflecting on prevailing knowledge “gaps”. We will consider modalities that may improve risk stratification and thereby optimize management in the future.

Test of Cure: strategies for the follow up of women treated for cervical intraepithelial neoplasia

C. Cocuzza (Italy) - K. Cuschieri (UK)

Debate on Controversial Topics

E. Franco (Canada) / K. Louvanto (Finland) / E. Siegler (Israel)

Debate sessions have been a popular offering in EUROGIN congresses since the 1990s. Pairs of leaders in the field capture the arguments on opposing sides of controversial or hot topics in HPV science and its practical aspects, such as vaccination, cervical cancer screening, and disease aetiology. They present their arguments and then debate each other. The session in 2022 will showcase debates between camps on five key areas: (i) clinical utility of HPV genotyping, (ii) adequacy of single-dose vaccination, (iii) VIA vs. HPV for cervical cancer screening in low resource settings, (iv) value of biomarkers for primary screening, and (v) feasibility of ending cervical cancer screening.

Other Topics

Who should be referred for high-resolution anoscopy (HRA)? And what if HRA is not available?

A. Nyitray (USA) - L. Abramowitz (France)

Biomarkers are under development to support decision-making about who should be referred to HRA. This session will first provide a state of the science overview about biomarkers to support anal precancer screening programs. However, there will be jurisdictions that will not have enough skilled anoscopists for many years, if ever. Clinicians in these areas cannot use biomarkers for precancers if positive results cannot be followed up with HRA. What are screening options for these clinicians who want to detect an anal malignancy as early as possible?

Heterogeneity of cervical precancers: what is new?

J. Doorbar (USA)

Screening and vaccination implementation in Eastern and Central Europe – part of Europe with highest burden (incidence, mortality) of cervical cancer

M. Poljak (Slovenia)

Digital interventions directed toward both patients and healthcare providers

G. Zimet (USA) - G. Woodall (USA)

Young Scientists Pitch Competition

J. Bonde (Denmark)

The EUROGIN Young Scientists Pitch Competition is a new initiative designed to give young scientists (35 yrs or less) the opportunity to be recognized for their research in HPV and its related diseases. During this session, 6 selected finalists will be invited on stage to present their pitch in fast-paced segments. Each young scientist will have 5 minutes to present their pitch to a jury of distinguished experts and the audience. The winner will be announced at the end of the session and will receive a 1000 euros travel grant.

Specialized Workshops

Cervical cancer screening workshop

S. Van Dijk (Netherlands) - P. Giorgi Rossi (Italy) - M. Rebolj (UK) - M. Elfström (Sweden)

Colposcopy course

A. Singer (UK) - J. Bornstein (Israel)

Workshop Espanola